Molecular Mechanisms of HIV Protease Inhibitors Against HPV-Associated Cervical Cancer: Restoration of TP53 Tumour Suppressor Activities [PDF]
Frontiers in Molecular Biosciences, 2022 Cervical cancer is a Human Papilloma virus-related disease, which is on the rise in a number of countries, globally. Two essential oncogenes, E6 and E7, drive cell transformation and cancer development.
Lilian Makgoo +2 more
doaj +2 more sources
Susceptibility of HPV-18 Cancer Cells to HIV Protease Inhibitors [PDF]
VirusesCervical cancer cases continue to rise despite all the advanced screening and preventative measures put in place, which include human papillomavirus (HPV) vaccination.
Lilian Makgoo +2 more
doaj +2 more sources
A folding inhibitor of the HIV-1 Protease [PDF]
Proteins: Structure, Function, and Bioinformatics, 2005 Being the HIV-1 Protease (HIV-1-PR) an essential enzyme in the viral life cycle, its inhibition can control AIDS. The folding of single domain proteins, like each of the monomers forming the HIV-1-PR homodimer, is controlled by local elementary ...
Abkevich +35 more
core +5 more sources
Developing HIV-1 Protease Inhibitors through Stereospecific Reactions in Protein Crystals [PDF]
Molecules, 2016 Protease inhibitors are key components in the chemotherapy of HIV infection. However, the appearance of viral mutants routinely compromises their clinical efficacy, creating a constant need for new and more potent inhibitors.
Folasade M. Olajuyigbe +3 more
doaj +3 more sources
Computational Simulation of HIV Protease Inhibitors to the Main Protease (Mpro) of SARS-CoV-2: Implications for COVID-19 Drugs Design [PDF]
Molecules, 2021 SARS-CoV-2 is highly homologous to SARS-CoV. To date, the main protease (Mpro) of SARS-CoV-2 is regarded as an important drug target for the treatment of Coronavirus Disease 2019 (COVID-19). Some experiments confirmed that several HIV protease inhibitors
Wei Yu +14 more
doaj +2 more sources
HIV protease inhibitors restore amphotericin B activity against Candida. [PDF]
PLoS ONECandida auris is an invasive fungal pathogen, representing a global public health threat. It is characterized by high mortality rates among infected individuals, significant antifungal resistance, and a remarkable ability to persist in healthcare ...
Yehia Elgammal +2 more
doaj +2 more sources
HIV-1 Protease Inhibitors [PDF]
Clinical Infectious Diseases, 2000 Treatment of human immunodeficiency virus type 1 (HIV-1) infection with regimens that include protease inhibitors (PIs) has contributed to marked improvements in HIV-related disease progression and mortality. Five PIs are approved by the US Food and Drug Administration and have potent activity in vitro.
Joseph J. Eron
openalex +4 more sources
Role of Gag in HIV Resistance to Protease Inhibitors [PDF]
Viruses, 2010 Cleavage of Gag and Gag-Pol precursors by the viral protease is an essential step in the replication cycle of HIV. Protease inhibitors, which compete with natural cleavage sites, strongly impair viral infectivity and have proven to be highly valuable in ...
Fabrizio Mammano, François Clavel
doaj +5 more sources
HIV protease inhibitors: a review of molecular selectivity and toxicity [PDF]
HIV/AIDS: Research and Palliative Care, 2015 Zhengtong Lv,* Yuan Chu,* Yong Wang Department of Immunology, School of Basic Medical Science, Xiangya School of Medicine, Central South University, Changsha, Hunan, People's Republic of China *Both authors contributed equally to this work ...
Lv Z, Chu Y, Wang Y
doaj +2 more sources
Current and Novel Inhibitors of HIV Protease
Viruses, 2009 The design, development and clinical success of HIV protease inhibitors represent one of the most remarkable achievements of molecular medicine. This review describes all nine currently available FDA-approved protease inhibitors, discusses their ...
Jan Konvalinka +3 more
doaj +4 more sources